Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Enteris BioPharma to Present at the 25th Annual Future Leaders in the Biotech Industry Conference


BOONTON, N.J., March 15, 2018 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced that Brian Zietsman, President and Chief Financial Officer of Enteris BioPharma, will present at the 25th Annual Future Leaders in the Biotech Industry Conference being held March 23, 2018, at the Millennium Broadway Hotel & Conference Center in New York City.

Mr. Zietsman will present Enteris' corporate growth strategy and its focus on developing orally delivered peptide therapeutics for a broad range of treatment indications. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligencetm platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class II, III and IV small molecules.

Most recently, Enteris announced positive results from the Phase 2a clinical trial of Ovarest®, an oral formulation of leuprolide, for the treatment of endometriosis. Data from the study indicated that Ovarest enabled significant suppression of estradiol (E2), demonstrating a measurable pharmacodynamic effect that is tightly correlated with efficacy in endometriosis.

Event:


25th Annual Future Leaders in the Biotech Industry Conference

Date: 


Friday, March 23, 2018

Time: 


2:30 p.m. (Eastern Time) 

Location:


Millennium Broadway Hotel & Conference Center ? Room 402/403 

About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company's proprietary oral delivery technology ? Peptelligence® ? has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma's most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is an oral peptide being developed for the treatment of endometriosis. Tobrate® (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI).  A third internal compound, octreotide, will be entering preclinical development in 2018. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.

For Enteris BioPharma:           

Brian Zietsman, President & CFO
+1.973.453.3527
 

Enteris Media Relations:

Jason Rando

Tiberend Strategic Advisors, Inc.

+1.212.375.2665

[email protected]

 

SOURCE Enteris BioPharma, Inc.


These press releases may also interest you

at 14:00
Neuroscientists have established in recent decades the idea that some of each day's experiences are converted by the brain into permanent memories during sleep the same night. Now, a new study proposes a mechanism that determines which memories are...

at 14:00
While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which...

at 13:55
An expert panel has published the first performance measures to identify remission and evaluate the effectiveness of lifestyle medicine treatments, which will allow more objective comparisons between lifestyle behavior interventions and other...

at 13:51
BRIJ Medical proudly welcomes three distinguished industry leaders to its Board of Directors: John Grotting, Bob Zollars, and Jim Hinrichs. Leveraging their extensive experience and insights, they will steer the company's strategic vision and drive...

at 13:47
Everyone deserves to succeed. But today, for too many Canadians, your hard work isn't paying off like it did for previous generations. Your paycheque doesn't go as far as costs go up, and saving enough to go after your dreams seems harder and harder....

at 13:41
With sadness, AAD announced today that its influential board member and investor James Herbert has died following a lengthy battle with cancer. He was 83....



News published on and distributed by: